Protein A Resin Market in terms of revenue was estimated to be worth $1.2 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 9.8% from 2022 to 2028 according to a new report by MarketsandMarkets™. Factors such as increasing research activities, expanding therapeutic applications of monoclonal antibodies, private along with public fundings, spending on pharmaceutical R&D, growing food safety concerns, and stringent regulatory control in healthcare are expected to propel the growth of this market. However, the high cost of the resin is expected to restrain the market growth.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19196962
Browse in-depth TOC on “Protein A Resin Market”
78 – Tables
35 – Figures
147 – Pages
Key Market Players
prominent players in the Protein A resin are Danaher Corporation (US), Merck KGAa (Germany) and Repligen Corporation (US) among others.
Protein A resin Market Dynamics
Drivers: Increasing demand for therapeutic antibodies
Chromatography is an essential step in the purification of monoclonal antibodies (mAbs). Over the past decade, there has been a tremendous increase in the demand for monoclonal antibodies in oncology and several other therapeutic areas, including neurological, autoimmune, and inflammatory disorders. As a result, almost all major pharmaceutical companies are focusing on the R&D of therapeutic antibodies.
Restraints: High cost of resins
Protein A resins cost around 5–10 times more than other types of resins. Though there are no alternative techniques that can achieve purification levels as high as protein A resins, their high cost makes end users look for alternatives. Some of the techniques that provide acceptable levels of purification include both chromatography and non-chromatography methods. mAb crystallization and precipitation by polyethylene glycol (PEG) precipitation are being explored as alternatives for protein A chromatography.
Opportunities: Increasing number of CMOs and CROs
An increasing number of CMOs and CROs are offering their services to pharmaceutical companies across the globe. This is expected to offer potential growth opportunities to protein A resin manufacturers during the forecast period.
Pharmaceutical companies are increasingly relying on contract manufacturers in various areas of research to fulfill a number of basic needs, such as specialized competencies and cost reduction. The pharmaceutical contract manufacturing industry has experienced robust growth in recent years, and this trend is expected to continue in the coming years. The increasing pressure from several governments to reduce healthcare costs and declining R&D productivity have compelled core pharmaceutical producers to rely on contract manufacturing. Moreover, the rising demand for generic drugs in China and India is a key driver for CMO sales.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=19196962
Challenges: Issues associated with scaling up production of protein A resins
The production of protein A resins is a complex process that involves many steps, including fermentation, extraction, purification, and packaging. Scaling up the production process to meet the growing demand requires careful planning and management to ensure consistency and quality throughout the production process.
Europe to register a significant growth in the market during the forecast period
Europe is expected to register a significant growth in the market during the forecast period. Europe comprises the Germany, France, UK, Italy, Spain, ROE. Factors such as the flourishing biotechnology industry and favourable healthcare and R&D scenarios are driving the growth of the Europe protein A resin market.
Recent Developments:
- As part of its charitable efforts through the Agilent Foundation, Agilent Technologies partnered with Delaware State University (DSU) to boost the number of minority students who choose STEM careers.
- Tosoh Biosciences LLC completed the acquisition of Semba Biosciences, a privately held leading innovator in the field of multi-column chromatography (MCC) instrumentation and technology for the downstream purification of biologics.
- Repligen and Navigo completed their co-development of a novel affinity ligand that addresses aggregation issues associated with pH-sensitive antibodies and Fc-fusion proteins. This ligand, NGL-Impact HipH, is produced and supplied to Purolite for use in a platform usage resin product.
- The Life Sciences business of GE Healthcare was acquired by Danaher Corporation and rebranded as Cytiva.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=19196962
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/protein-a-resin-market-19196962.html